Keyword : breast cancer
Therapeutic options for breast cancer with low HER2/NEU expressionAuthors: Chovgan O.E. Samuseva A.A. Lyalkin S.A. Дата: 2026-01-16
Trastuzumab deruxtecan in the treatment of HER2-positive metastatic breast cancer
The use of contrast-enhanced spectral mammography in monitoring neoadjuvant treatment of breast cancer: a clinical case studyAuthors: Karacharova I.Yu. Malets M.S. Gurando A.V. Starenkyi V.P. Дата: 2025-12-02
A Multidisciplinary Approach to Breast Cancer Treatment in Historical Perspective
Cost minimization analysis of neoadjuvant treatment of luminal B HER2/neu-negative breast cancer: chemotherapy versus hormone therapyAuthors: Artemenko M.V. Bondarenko I.M. Zavizion V.F. Avierin D.I. Т. 14, №4 (56)
Features of immune microenvironment in Her2 low breast cancerAuthors: Lyalkin S.A. Krotevich M.S. Smolanka I.I. Shudrak P.A.... Т. 14, №3 (55)
Neoadjuvant endocrine therapy of breast cancer: history and modern views of the problem
Authors: Zavizion V.F. Artemenko M.V. Т. 14, №3 (55)
Authors: Zavizion V.F. Artemenko M.V. Т. 14, №3 (55)
Assessment of the toxicity profile and safety of integrating metformin into neoadjuvant chemotherapy for breast cancerAuthors: Avierin D. Zavizion V. Т. 14, №2 (54)
Analysis of the relationship between Ki-67 expression dynamic and RECIST 1.1 dynamic during neoadjuvant breast cancer chemotherapy. Prediction of morphological responseAuthors: Avierin D. Zavizion V. Т. 14, №1 (53)
Plasma miRNA levels in breast cancer patients and their correlation with clinical characteristics as a measure of individualized treatment
Author:Harashchenko О. Т. 14, №1 (53)
Author:Harashchenko О. Т. 14, №1 (53)
New stage in personalized breast cancer therapy: a chance for recovery
Treatment of patients with recurrent and metastatic forms of breast cancerAuthors: Ivankova V.S. Baranovska L.M. Stoliarova O.Yu. Ivankova O.M.... Т. 13, № 3 (51)
New stage in personalized breast cancer therapy: a chance for recovery
The course features of HER2/neu-low breast cancerAuthors: Bondar M.V. Syvak L.A. Tarasenko T.Ye. Martynyuk O.M.... Т. 13, № 2 (50)
Clinical characteristics, treatment characteristics, and endpoints assessed in real-world clinical practice of talazoparib in patients with HER2-negative BRCA-associated breast cancerAuthor:Huyvanyuk O.A. Т. 13, № 2 (50)
